In this issue:
Adding bortezomib to melphalan conditioning does not improve outcomes
Significant survival advantage to maintenance after early or delayed ASCT
AlloSCT plus novel drugs for high-risk disease
Cilta-cel superior to conventional therapy for RRMM
Adjunct PET/CT improves treatment response evaluation
Persistent opioid use in patients with MM after transplant
Impaired quality of life and misperceptions about curability in all stages of disease
NLR a biomarker of frailty and survival in MM
NGS may aid in diagnosing myeloid neoplasms in MM patients with cytopenia
Kidney transplant feasible for patients with MM-related renal failure
Please login below to download this issue (PDF)